Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.53 |
| ▸ | POLA1 | P09884 | 2/20 | 0.50 |
| ▸ | MMP3 | P08254 | 6/20 | 0.47 |
| ▸ | MMP9 | P14780 | 6/20 | 0.47 |
| ▸ | MMP8 | P22894 | 6/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20561169 | 1.00 | NR1H2 (0.53) | NR1H2NR1H3POLA1MMP3MMP9 | |
| SCHEMBL20561252 | 0.91 | NR1H2 (0.59) | NR1H2NR1H3POLA1MMP3MMP9 | |
| SCHEMBL20561122 | 0.89 | NR1H2 (0.66) | NR1H2NR1H3POLA1PTPN1 | |
| SCHEMBL6310538 | 0.89 | NR1H2 (0.66) | NR1H2NR1H3POLA1PTPN1 | |
| SCHEMBL29562156 | 0.89 | NR1H2 (0.55) | NR1H2NR1H3POLA1MMP3MMP9 | |
| SCHEMBL27944668 | 0.86 | NR1H2 (0.55) | NR1H2NR1H3POLA1 | |
| SCHEMBL27944666 | 0.86 | NR1H2 (0.55) | NR1H2NR1H3POLA1 | |
| SCHEMBL24591832 | 0.86 | NR1H2 (0.50) | NR1H2NR1H3POLA1MMP3MMP9 | |
| SCHEMBL29493614 | 0.86 | NR1H2 (0.50) | NR1H2NR1H3POLA1MMP3MMP9 | |
| SCHEMBL29493590 | 0.85 | NR1H2 (0.73) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589101-B2 | Cyclodextrin protein drug conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250270163-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMA (US) | 2025-08-28 | — | — | US | disclosed |
| US-12338199-B2 | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250171622-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12209180-B2 | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists | REGENERON PHARMACEUTICALS, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240408223-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMA (US) | 2024-12-12 | — | — | US | disclosed |
| US-12134631-B2 | Hydrophilic linkers for antibody drug conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4428142-A2 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-3883926-B1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMA (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11491237-B2 | Cyclodextrin protein drug conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20220080052-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMACEUTICALS, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209180-B2 | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885POLA1 2346/4885 |
| US-11491237-B2 | Cyclodextrin protein drug conjugates | SDCBP, DDOST, KRTCAP2 | NR1H2 1304/4885NR1H3 1332/4885POLA1 4011/4885 |
| US-12338199-B2 | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | NR1H4, NR1H3, OGFR | NR1H2 4/4885NR1H3 2/4885POLA1 2752/4885 |
| US-12589101-B2 | Cyclodextrin protein drug conjugates | SSB, CHP1, IAPP | NR1H2 3598/4885NR1H3 3733/4885POLA1 1696/4885 |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | CD47, MSR1, LDLR | NR1H2 195/4885NR1H3 128/4885POLA1 2693/4885 |
| US-20250171622-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885POLA1 2346/4885 |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | NR1H2 4/4885NR1H3 2/4885POLA1 2752/4885 |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | SDCBP, DDOST, KRTCAP2 | NR1H2 1304/4885NR1H3 1332/4885POLA1 4011/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | NR1H2 195/4885NR1H3 128/4885POLA1 2693/4885 |
| US-12134631-B2 | Hydrophilic linkers for antibody drug conjugates | CD44, CD47, EPCAM | NR1H2 3175/4885NR1H3 2873/4885POLA1 3401/4885 |
| US-20250270163-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | NR1H2 4/4885NR1H3 2/4885POLA1 2752/4885 |
| US-20220080052-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885POLA1 2346/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | NR1H2 195/4885NR1H3 128/4885POLA1 2693/4885 |
| US-20240408223-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | NR1H2 3175/4885NR1H3 2873/4885POLA1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.